In its steadfast commitment to enhancing quality healthcare access, Mankind Pharma, a leading pharmaceutical company is proud to unveil a significant stride with the introduction of 120 DMF (Drug Master File) Quality Medicines in the Indian market.
Committed to delivering exceptional healthcare solutions at affordable rates, Mankind Pharma’s initiative aims to ensure universal access to medicines of international calibre.
India stands as a global leader in offering generic medicines that adhere to the stringent DMF quality standards set for Active Pharmaceutical Ingredients (APIs).
Mankind Pharma takes a pioneering step by introducing DMF quality API in the Indian market, which is manufacture in a USFDA-approve plant.
Thus, the final medicine is always one of the best quality with better efficacy. DMF Quality API represents a pinnacle of excellence that surpasses conventional standards.
The medicines in the USA comply with stringent USFDA’s norms for quality, safety and effectiveness; defined by DMF (Drug Master File).
The Drug Master File (DMF) has all the information on an API (Active Pharmaceutical Ingredient/Raw material for medicine).
It provides all the information on the manufacturing, stability, quality, packaging, purity and impurity profile for authorities to ensure that medicines have the best quality and efficacy.
DMF quality API is purer than normal API because it follows US pharmacopeia and is manufacture in USFDA-approve plants for medicines that are of best quality and efficacy.
Mr Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma Said :
“Introducing over 120 DMF Quality Medicines reflects Mankind Pharma’s unwavering commitment to delivering healthcare solutions of exceptional quality. At Mankind, we believe that every Indian, irrespective of their economic background, has the right to get medicines of International quality. As we launch this comprehensive range, we aim to bridge gaps in healthcare accessibility, ensuring that every individual in India can access medicines that are of the highest USFDA approved standards. This initiative resonates with our motto of ‘Serving Life,’ and underscores our dedication to enriching lives through accessible and reliable healthcare”
The company’s commitment to offering premium healthcare solutions that cater to all strata of society is reinforce by this ground-breaking initiative.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.
Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices.
The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas.
This includes products for anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, VMN and respiratory diseases, among many others with a strategy to increase market presence/ share for chronic ailments.
In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with many category-leading brands.
The company has 25 manufacturing facilities across India and has over four thousand manufacturing personnel as of December 31, 2022.
Manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.
Mankind has a consistent track record of product innovation, as of 31st December, 2022, Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.
